Universal Health Services shares are down about 3% as the market reacts to two near-term overhangs hitting at once: a newly reported change to its bank credit agreement that adds $900 million in new term loans, and renewed legal noise from an announced stockholder investigation. With UHS set to report quarterly results on April 27, traders are also de-risking into the print as attention shifts to volumes, labor costs, and 2026 guidance execution.

A credit-agreement amendment effective April 22, 2026 added three new term-loan components totaling $900 million. Even when leverage remains manageable, incremental borrowing can raise questions about interest expense, capital allocation priorities, and whether management is positioning for refinancing, M&A, or other uses of cash at a time when hospital operators are navigating wage inflation and utilization variability. The disclosure also circulated alongside a notable price-target cut by at least one firm while maintaining a neutral-style stance, reinforcing a cautious tone into earnings.

Separately, a plaintiff law firm announced it is investigating UHS on behalf of shareholders, which can amplify uncertainty regardless of ultimate merit. These releases often trigger short-term selling because they introduce headline risk and potential costs, and they can keep investors on the sidelines until the company’s next earnings call provides clearer operating and financial direction.

The next catalyst is UHS’s April 27 earnings release and the April 28 conference call timing widely tracked by markets. Investors will be listening for updates on behavioral health and acute-care volumes, labor and contract staffing trends, and whether full-year 2026 targets remain intact given the evolving cost of capital and any additional non-operating items.